StockData

Hyperfine vs Lifeward

HYPR and LFWD side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How HYPR and LFWD compare

Hyperfine is the larger company, worth 6.8 times as much as Lifeward ($59.6M against $8.8M).

Hyperfine grew revenue faster over the last twelve months (53.2% versus −10.7% for Lifeward).

Lifeward keeps more of each dollar of sales as profit, with a net margin of −141% compared with −211% at Hyperfine.

Lifeward scores higher on the StockData Score (11 against 9 for Hyperfine), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricHYPRLFWD
Size and price
Market cap$59.6M$8.8M
Share price$0.562$3.10
Change, 1 year−51.2%−56.8%
Change, 5 years−94.3%−97.3%
Beta (5Y)1.251.20
Employees10281
StockData Score
Total score911 (better)
Valuation score33
Growth score3 (better)2
Performance score11
Health score25 (better)
Dividend score00
Valuation
P/S3.6×0.4× (better)
P/B1.6×0.7× (better)
FCF yield−46.2% (better)−195%
Fair value$0.778$13.92
Margin of safety27.8%77.7% (better)
Growth
Revenue growth (TTM)53.2% (better)−10.7%
Revenue growth, 5Y average115% (better)38.1%
Profitability
Gross margin51.4% (better)36.0%
Operating margin−203%−104% (better)
Net margin−211%−141% (better)
FCF margin−166%−78.3% (better)
Return on equity−97.0% (better)−226%
Return on invested capital−327%−291% (better)
Financial health
Debt / equity0.36 (better)0.00
Current ratio6.15 (better)2.33
Altman Z-score−6.92 (better)−13.07
Piotroski F-score44
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions20.6%1.1%
Held by insiders18.1%90.3%
Insider net buying, 12 months−$91.9K–
Short interest, % of float4.5%31.9%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.